Lineage tracing of both quiescent G0 and active Hoxb5+ LT-HSCs that actively contribute to homeostatic mouse hematopoiesis
Abstract
Studying the lineage commitment and differentiation potential of long-term hematopoietic stem cells (LT-HSCs) is important to understand the dynamics of hematopoiesis. A central question concerns which hematopoietic stem and progenitor cell populations are responsible for sustaining steady-state hematopoiesis in vivo without conditioning. Noninvasive HSC fate-mapping strategies to address this question require specific labeling of LT-HSCs only. In this study, we selectively labeled a subset of Hoxb5+ LT-HSCs—excluding short-term HSCs (ST-HSCs) and multipotent progenitors (MPPs)—to track the progeny of these cells. Hoxb5+ LT-HSCs comprise ~1 in 100,000 bone marrow cells. MPPs were not labeled until several months post-induction, indicating their derivation from LT-HSCs. At no time were MPPs labeled and LT-HSCs not, consistent with the origin and maintenance of MPPs from LT-HSCs. Hoxb5+ LT-HSCs are the principal contributors to steady-state in situ hematopoiesis, but only a fraction of LT-HSCs were labeled by the Cre/LoxP conversion to a lineage-tracing color. We tested whether quiescent HSCs could have incised the DNA at loxp sites, but did not finish the rearrangement. Analysis of phosphorylated H2AX (γ-H2AX) revealed that quiescent LT-HSCs retain Cre/LoxP-induced DNA incisions, which are repaired upon cell cycle entry, leading to the appearance of newly labeled LT-HSCs at later time points, mainly of the myeloid-biased HSC. Moreover, most LT-HSCs exhibit marked expansion in response to hematopoietic stress. With the age-related shift of blood formation from balanced to myeloid biased, the myeloid-biased HSCs expand preferentially after 6 mo of tracking.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Jinyi Xiang
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Laura Almeida
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Joe Pasillas
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Christopher T. Sun
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Yijun Wang
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Elle Koren
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Eric C. Hanson
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Annika Brakebill
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Charlene Wang
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Andrew T. Burden
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University
Irving L. Weissman